RNXT

MKT CAP:$31M

RenovoRx, Inc.

Market Cap

$31M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.90+$0.06 (+7.76%)

Apr 23, 2026

Company Details

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine a...

CEO

Shaun R. Bagai

IPO Date

Aug 26, 2021

Website

renovorx.com

Key Metrics TTM

Revenue

$1M

+2511.6% YoY

Net Income

-$11M

EPS (Diluted)

-$0.32

Free Cash Flow

-$11M

Revenue / Share

$0.03

Gross Margin

70.9%

Operating Margin

-1114.0%

Net Margin

-994.5%

FCF Margin

-977.3%

P/S

27.9x

P/E

—

Earnings Reports

FY 2025

Mar 30, 2026

$1M+2511.6%EPS -$0.32

Q4 2025

Mar 30, 2026

$238.0K+453.5%EPS -$0.08

Q3 2025

Nov 13, 2025

$266.0KEPS -$0.08

Q2 2025

Aug 14, 2025

$422.0KEPS -$0.08

Q1 2025

May 15, 2025

$197.0KEPS -$0.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$3M
Q2 22	$0	$0	-$3M
Q3 22	$0	$0	-$2M
Q4 22	$0	$0	-$2M
Q1 23	$0	$0	-$3M
Q2 23	$0	$0	-$3M
Q3 23	$0	$0	-$3M
Q4 23	$0	$0	-$2M
Q1 24	$0	$0	-$2M
Q2 24	$0	$0	-$3M
Q3 24	$0	$0	-$3M
Q4 24	$43.0K	$43.0K	-$3M
Q1 25	$197.0K	$103.0K	-$3M
Q2 25	$422.0K	$270.0K	-$3M
Q3 25	$266.0K	$213.0K	-$3M
Q4 25	$238.0K	$210.0K	-$4M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	806.2x	—
Q1 25	918.7x	—
Q2 25	62.6x	—
Q3 25	46.5x	—
Q4 25	26.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$2M	-$2M
Q2 22	-$2M	-$2M
Q3 22	-$3M	-$3M
Q4 22	-$2M	-$2M
Q1 23	-$3M	-$3M
Q2 23	-$3M	-$3M
Q3 23	-$3M	-$3M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$2M	-$2M
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$3M	-$3M
Q2 25	-$2M	-$2M
Q3 25	-$2M	-$2M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$12.0K
Q1 25	$2.0K
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+185.4%
Q2 22	—	+201.8%
Q3 22	—	+54.9%
Q4 22	—	-7.9%
Q1 23	—	+8.5%
Q2 23	—	+29.1%
Q3 23	—	+38.0%
Q4 23	—	-18.1%
Q1 24	—	-24.1%
Q2 24	—	-10.1%
Q3 24	—	-5.2%
Q4 24	—	+50.5%
Q1 25	—	+33.6%
Q2 25	—	+2.2%
Q3 25	—	+22.6%
Q4 25	+453.5%	+40.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$168.0K	—
Q2 22	$169.0K	—
Q3 22	$143.0K	—
Q4 22	$164.0K	—
Q1 23	$361.0K	—
Q2 23	$257.0K	—
Q3 23	$239.0K	—
Q4 23	$221.0K	—
Q1 24	$423.0K	—
Q2 24	$244.0K	—
Q3 24	$255.0K	—
Q4 24	$252.0K	586.0%
Q1 25	$288.0K	146.2%
Q2 25	$345.0K	81.8%
Q3 25	$349.0K	131.2%
Q4 25	$285.0K	119.7%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$1M	$2M	—
Q2 22	$1M	$1M	—
Q3 22	$846.0K	$1M	—
Q4 22	$776.0K	$1M	—
Q1 23	$1M	$2M	—
Q2 23	$2M	$1M	—
Q3 23	$2M	$1M	—
Q4 23	$775.0K	$1M	—
Q1 24	$1M	$1M	—
Q2 24	$2M	$1M	—
Q3 24	$2M	$1M	—
Q4 24	$2M	$1M	—
Q1 25	$2M	$2M	—
Q2 25	$1M	$2M	—
Q3 25	$2M	—	$2M
Q4 25	$2M	$2M	—

Revenue Segments

Quarter	Other Operating Segment
Q1 25	$197.0K
Q2 25	$422.0K
Q3 25	$266.0K
Q4 25	$238.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$13M	$0	$13M
Q2 22	$3M	$8M	$11M
Q3 22	$3M	$5M	$8M
Q4 22	$4M	$2M	$6M
Q1 23	$4M	$0	$4M
Q2 23	$6M	$0	$6M
Q3 23	$3M	$0	$3M
Q4 23	$1M	$0	$1M
Q1 24	$4M	$0	$4M
Q2 24	$12M	$0	$12M
Q3 24	$10M	$0	$10M
Q4 24	$7M	$0	$7M
Q1 25	$15M	$0	$15M
Q2 25	$12M	$0	$12M
Q3 25	$10M	$0	$10M
Q4 25	$7M	$0	$7M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	18M	+60.0%	+7.3%
Q2 22	18M	+0.7%	+10.4%
Q3 22	18M	+0.1%	+61.3%
Q4 22	18M	+0.3%	+61.9%
Q1 23	18M	-0.1%	+1.1%
Q2 23	21M	+17.2%	+17.6%
Q3 23	21M	+0.4%	+17.9%
Q4 23	21M	+0.0%	+17.6%
Q1 24	30M	+39.8%	+64.4%
Q2 24	24M	-19.6%	+12.9%
Q3 24	25M	+3.7%	+16.6%
Q4 24	22M	-10.7%	+4.1%
Q1 25	31M	+41.0%	+5.0%
Q2 25	37M	+16.5%	+52.1%
Q3 25	37M	+0.2%	+46.9%
Q4 25	35M	-3.6%	+58.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	6
Q2 22	$0	6
Q3 22	$0	6
Q4 22	$0	9
Q1 23	$0	9
Q2 23	$0	9
Q3 23	$0	9
Q4 23	$0	8
Q1 24	$0	8
Q2 24	$0	8
Q3 24	$0	8
Q4 24	$4.3K	10
Q1 25	$19.7K	10
Q2 25	$42.2K	10
Q3 25	$26.6K	10
Q4 25	$1	200K

Revenue / Employee